NFA
OCUL icon

Nationwide Fund Advisors’s Ocular Therapeutix OCUL Stock Holding History

Nationwide Fund Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,344
Closed -$76K – 1433
2017
Q3 		$76K Hold
12,344
– – ﹤0.01% 2982
2017
Q2 		$114K Buy
12,344
+1,204
+11% +$11.7K ﹤0.01% 2847
2017
Q1 		$103K Hold
11,140
– – ﹤0.01% 2833
2016
Q4 		$93K Hold
11,140
– – ﹤0.01% 2895
2016
Q3 		$77K Hold
11,140
– – ﹤0.01% 2973
2016
Q2 		$55K Buy
11,140
+1,532
+16% +$15.2K ﹤0.01% 3064
2016
Q1 		$93K Hold
9,608
– – ﹤0.01% 2851
2015
Q4 		$90K Sell
9,608
-4,367
-31% -$47.1K ﹤0.01% 2882
2015
Q3 		$196K Buy
13,975
+856
+7% +$17.2K ﹤0.01% 2574
2015
Q2 		$276K Buy
13,119
+4,165
+47% +$103K ﹤0.01% 2545
2015
Q1 		$376K Buy
8,954
+4,415
+97% +$145K ﹤0.01% 2382
2014
Q4 		$107K Buy
4,539
+2,907
+178% +$48.9K ﹤0.01% 2893
2014
Q3 		$24K Buy
+1,632
New +$24.1K ﹤0.01% 3155

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nationwide Fund Advisors's OCUL Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2017, closing a stake of 12,344 shares — an estimated $76K sold.

Nationwide Fund Advisors first reported a position in OCUL in Q3 2014 and held it in 13 quarters. The position peaked at $376K in Q1 2015. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Ocular Therapeutix position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 12,344 Ocular Therapeutix shares in Q4 2017, an estimated $76K.
  • Nationwide Fund Advisors first reported a position in Ocular Therapeutix in Q3 2014 and held it in 13 quarters.
  • Nationwide Fund Advisors's Ocular Therapeutix position peaked at $376K in Q1 2015.
  • 69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.